Biogen's Spinraza (nusinersen) receives Notice of Compliance from Health Canada for the treatment of 5q spinal muscular atrophy

Biogen

4 July 2017 - First SMA treatment approval in Canada.

 Biogen Canada Inc. today announced that Health Canada has approved Spinraza (nusinersen) for the treatment of patients with 5q spinal muscular atrophy (SMA). 

Spinraza is the first treatment to be approved in Canada for SMA, a leading genetic cause of death in infants and toddlers that is marked by progressive, debilitating muscle weakness.

Spinraza is indicated for the treatment of 5q SMA, which is the most common form of the disease and represents approximately 95% of all SMA cases.

Read Biogen press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Canada , Gene therapy